Engineered Gene Therapy Vectors for Blood-Brain Barrier CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system (CNS) manifestations of diseases, such as lysosomal storage disorders, are hindered by the blood-brain barrier, with recombinant enzyme replacement therapies failing to effectively cross and treat neurological symptoms due to limited brain exposure.
Innovation Solution
A gene therapy vector comprising a transgene with a biologically active polypeptide, such as idursulfase or glucocerebrosidase, linked to a transferrin receptor-binding antigen-binding molecule (TAG) to enhance crossing of the blood-brain barrier, using a recombinant AAV vector with a promoter and posttranscriptional regulatory elements for sustained expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant enzyme replacement therapy is administered systemically, then peripheral tissue treatment is achieved, but CNS exposure is insufficient due to blood-brain barrier restrictions
Solution Approach 1:
The patent employs a transferrin receptor-binding tag (TB12) as an intermediary molecule that mediates the transport of therapeutic enzymes across the blood-brain barrier. This tag binds to the transferrin receptor on the BBB, facilitating receptor-mediated transcytosis and enabling therapeutic proteins to overcome the barrier restriction while maintaining their enzymatic activity in the CNS.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the therapeutic enzyme by fusing it with the TB12 tag, changing its molecular characteristics to enable BBB penetration. This parameter change allows the enzyme to interact with the transferrin receptor and be transported across the barrier, transforming it from a BBB-restricted molecule to a CNS-penetrating therapeutic.
2Quantity of substance
If direct CNS delivery approaches are used, then brain distribution is improved, but device complexity and invasiveness increase
Solution Approach 1:
The patent enables the therapeutic enzyme to deliver itself to the CNS through self-mediated transcytosis. The TB12 tag on the enzyme surface automatically binds to transferrin receptors on the BBB and facilitates its own transport into the brain, eliminating the need for external delivery devices or complex administration systems while achieving effective brain distribution.
3Quantity of substance
If first generation enzyme replacement therapy is used, then peripheral substrate reduction is achieved, but CNS substrate levels remain elevated
Solution Approach 1:
The TB12 tag acts as a mediator that enables therapeutic enzymes to penetrate the blood-brain barrier and reach the CNS, directly addressing the limitation of first-generation ERT that could reduce peripheral substrates but failed to lower CNS substrate levels. This intermediary facilitates reliable CNS treatment effectiveness.
Solution Approach 2:
By changing the molecular parameters of the enzyme through TB12 fusion, the patent transforms the enzyme's ability to penetrate the BBB, thereby improving its reliability in treating CNS manifestations of lysosomal storage disorders and achieving sustained substrate reduction in the brain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vector facilitates widespread CNS exposure of therapeutic enzymes, reducing substrate accumulation and alleviating CNS symptoms in diseases like Hunter syndrome and Gaucher disease, providing continuous treatment without repetitive dosing.
Implementation Method 1
The TAG increases the translocation of the biologically active polypeptide across the blood brain barrier
Data Source
AI summary
The present disclosure relates generally to viral vectors comprising an engineered transgene capable of crossing the blood brain barrier and uses thereof in the treatment of diseases presenting with central nervous system manifestations, such as, but not limited to Hunter syndrome, Gaucher disease, and Sanfilippo syndrome.